[go: up one dir, main page]

AR060362A1 - Agente para prevenir / tratar el cancer - Google Patents

Agente para prevenir / tratar el cancer

Info

Publication number
AR060362A1
AR060362A1 ARP070101453A ARP070101453A AR060362A1 AR 060362 A1 AR060362 A1 AR 060362A1 AR P070101453 A ARP070101453 A AR P070101453A AR P070101453 A ARP070101453 A AR P070101453A AR 060362 A1 AR060362 A1 AR 060362A1
Authority
AR
Argentina
Prior art keywords
agent
prevent
treat cancer
seq
amino acid
Prior art date
Application number
ARP070101453A
Other languages
English (en)
Inventor
S Sato
T Oshima
T Kurokawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Priority to CNA2007800371476A priority Critical patent/CN101541834A/zh
Priority to PCT/JP2007/069908 priority patent/WO2008044754A1/ja
Priority to CA002666249A priority patent/CA2666249A1/en
Priority to AU2007307536A priority patent/AU2007307536A1/en
Priority to BRPI0717024-6A2A priority patent/BRPI0717024A2/pt
Priority to EP07829644A priority patent/EP2067791A4/en
Priority to JP2008538759A priority patent/JPWO2008044754A1/ja
Priority to MX2009003126A priority patent/MX2009003126A/es
Priority to RU2009117237/10A priority patent/RU2009117237A/ru
Priority to PE2007001348A priority patent/PE20081456A1/es
Priority to KR1020097009036A priority patent/KR20090078339A/ko
Priority to US12/444,382 priority patent/US20100008928A1/en
Priority to CL200702879A priority patent/CL2007002879A1/es
Publication of AR060362A1 publication Critical patent/AR060362A1/es
Priority to IL197389A priority patent/IL197389A0/en
Priority to TN2009000090A priority patent/TN2009000090A1/fr
Priority to CR10676A priority patent/CR10676A/es
Priority to EC2009009276A priority patent/ECSP099276A/es
Priority to MA31823A priority patent/MA30816B1/fr
Priority to CO09044621A priority patent/CO6190538A2/es
Priority to NO20091783A priority patent/NO20091783L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/575—
    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un anticuerpo monoclonal humano contra una proteína que comprende la misma o sustancialmente la misma secuencia de aminoácidos que la secuencia de aminoácidos representada por la SEC ID N°:1 o SEC ID N°: 3, su péptido parcial o una sal del mismo, es util como agente para prevenir/tratar el cáncer, etc., un inductor de apoptosis de células cancerosas, un inhibidor del crecimiento de células cancerosas, un agente citotoxico contra células cancerosas a través de un mecanismo de defensa del huésped mediado por la region FC de un anticuerpo y demás.
ARP070101453A 2005-10-07 2007-04-04 Agente para prevenir / tratar el cancer AR060362A1 (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
PE2007001348A PE20081456A1 (es) 2006-10-06 2007-10-04 Anticuerpo monoclonal contra nectina 2
KR1020097009036A KR20090078339A (ko) 2006-10-06 2007-10-04 암의 예방·치료제
CA002666249A CA2666249A1 (en) 2006-10-06 2007-10-04 Agent for preventing/treating cancer
AU2007307536A AU2007307536A1 (en) 2006-10-06 2007-10-04 Agent for preventing/treating cancer
BRPI0717024-6A2A BRPI0717024A2 (pt) 2006-10-06 2007-10-04 Anticorpo, célula de hibridoma, agente de diagnótico, medicamento, métodos para prevenir/tratar câncer, para induzir apoptose células cancerosas , para inibir crescimento de células cancerosas e para destruir células cancerosas, uso de um anicorpo monoclonal e agente para prevenir ou tratar câncer de mama.
EP07829644A EP2067791A4 (en) 2006-10-06 2007-10-04 PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST CANCER
JP2008538759A JPWO2008044754A1 (ja) 2006-10-06 2007-10-04 癌の予防・治療剤
MX2009003126A MX2009003126A (es) 2006-10-06 2007-10-04 Agente para prevenir/tratar el cancer.
RU2009117237/10A RU2009117237A (ru) 2006-10-06 2007-10-04 Средство для профилактики/лечения рака
CNA2007800371476A CN101541834A (zh) 2006-10-06 2007-10-04 癌症的预防和/或治疗剂
US12/444,382 US20100008928A1 (en) 2006-10-06 2007-10-04 Agent for preventing/treating cancer
PCT/JP2007/069908 WO2008044754A1 (en) 2006-10-06 2007-10-04 Prophylactic or therapeutic agent for cancer
CL200702879A CL2007002879A1 (es) 2007-04-04 2007-10-05 Anticuerpo monoclonal contra nectina-2; celula de hibridoma que lo produce; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
IL197389A IL197389A0 (en) 2006-10-06 2009-03-03 Prophylactic or therapeutic agent for cancer
TN2009000090A TN2009000090A1 (en) 2007-04-04 2009-03-16 Prophylactic or therapeutic agent for canger
CR10676A CR10676A (es) 2006-10-06 2009-03-20 Agente para prevenir/ tratar el cancer
EC2009009276A ECSP099276A (es) 2006-10-06 2009-04-23 Agente para prevenir/tratar el cancer
MA31823A MA30816B1 (fr) 2006-10-06 2009-04-27 Agent prophylactique ou therapeutique pour le cancer
CO09044621A CO6190538A2 (es) 2006-10-06 2009-05-04 Agente para prevenir/tratar el cancer
NO20091783A NO20091783L (no) 2006-10-06 2009-05-05 Middel for a forebygge/behandle kreft

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005295146 2005-10-07
PCT/JP2006/320429 WO2007043635A1 (ja) 2005-10-07 2006-10-06 癌の予防・治療剤

Publications (1)

Publication Number Publication Date
AR060362A1 true AR060362A1 (es) 2008-06-11

Family

ID=37942856

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101453A AR060362A1 (es) 2005-10-07 2007-04-04 Agente para prevenir / tratar el cancer

Country Status (9)

Country Link
US (1) US20090142346A1 (es)
EP (1) EP1932857A1 (es)
JP (1) JPWO2007043635A1 (es)
AR (1) AR060362A1 (es)
CA (1) CA2639119A1 (es)
CL (1) CL2007000974A1 (es)
PE (1) PE20080909A1 (es)
TW (1) TW200840825A (es)
WO (1) WO2007043635A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2824389A1 (en) * 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
KR20190057354A (ko) * 2016-09-23 2019-05-28 티에프케이 가부시키가이샤 화합물 또는 그 염, 항염증제, 폐암에 대한 항암제, 화합물 또는 그 염의 제조 방법, 염증성 질환의 치료 방법 및 폐암의 치료 방법
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
CA3125962A1 (en) * 2019-01-13 2020-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human nectin-2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129685A1 (en) * 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
MXPA03002479A (es) * 2000-10-05 2004-05-24 Immunex Corp Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
EP2070546A1 (en) * 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer

Also Published As

Publication number Publication date
US20090142346A1 (en) 2009-06-04
EP1932857A1 (en) 2008-06-18
WO2007043635A1 (ja) 2007-04-19
TW200840825A (en) 2008-10-16
CL2007000974A1 (es) 2008-05-02
CA2639119A1 (en) 2007-04-19
PE20080909A1 (es) 2008-08-28
JPWO2007043635A1 (ja) 2009-04-16

Similar Documents

Publication Publication Date Title
AR063153A1 (es) Anticuerpo monoclonal para prevenir/tratar el cancer
ES2531083T3 (es) Formulaciones estables de polipéptidos y usos de las mismas
PE20110310A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
AR077096A1 (es) Toxinas cry insecticidas dig-11 de bacillus thuringiensis
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
NO20063026L (no) Antistoffer
CO6450656A2 (es) Anticuerpos anti-tnf-alfa y sus usos
AR073237A1 (es) Proteinas de bacillus thuringiensis que son toxinas activas contra hemipteros y coleopteros
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
NO20082510L (no) En fremgangsmate for konsentrasjon av et polypeptid
CR10347A (es) Anticuerpos contra el peptidob-amiloide
EA201491049A1 (ru) Противораковый слитый белок
CA2648109A1 (en) Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine
NI201200134A (es) Polipéptidos agonistas que se enlazan a dr5
EA201390820A1 (ru) Слитый белок против рака
WO2011020089A3 (en) Target genes for cancer therapy
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
PE20080187A1 (es) Agonistas receptores de eritropoietina
AR060362A1 (es) Agente para prevenir / tratar el cancer
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
EA201391546A1 (ru) Противораковый слитый белок
ATE509958T1 (de) Gegen cathepsin s gerichtete therapie

Legal Events

Date Code Title Description
FB Suspension of granting procedure